At least one patient with diabetic limb ulcers will be pleased that they participated in Osprey Medical's (ASX:OSP) Limb Recovery trial
At least one patient with diabetic limb ulcers will be pleased that they participated in Osprey Medical's (ASX:OSP) Limb Recovery trial. In a presentation at the Diabetic Foot Global Conference last month, the primary investigator in this 5-patient pilot trial reported that OSP's Limb Recovery system was safe and able to get much needed antibiotics into the limbs of these patients. Normally treating infections in these patients is difficult as the circulation in their limbs is so compromised that it cannot deliver the drugs. OSP's Limb Recovery system creates a temporary, closed circulatory system that allows high levels of antibiotics to be delivered to the site of infection. This resulted in a significant reduction in the level of bacteria and, in at least one patient, the retention of a much-loved limb that was scheduled for amputation. Results from a 20-patient controlled trial of the system are expected later this year.
PhD Human Genetics, MBA, BSc Hons (1st Class). Sell side analyst specialising in life science companies since 2006. Previous background in biotech companies, medical research, consulting with BCG and scientific journalism with Nature
No areas of expertise